ZDoggMD on Big Pharma: Drug Pricing, Direct-to-Consumer Advertising, and Physician Influence

This article discusses ideas from ZDoggMD — Dr. Zubin Damania, MD , Stanford/UCSF-trained internist, founder of the Health 3.0 movement. Full archive: zdoggmd.com | YouTube @zdoggmd

ZDoggMD's relationship with the pharmaceutical industry is complicated, as it should be. Pharmaceutical innovation has produced treatments that genuinely save lives. Pharmaceutical industry practices — pricing opacity, aggressive marketing, regulatory manipulation — have caused real harm. Holding both truths simultaneously is essential to ZDoggMD's Health 3.0 framework.

Drug Pricing: The Uniquely American Problem

The United States pays dramatically more for pharmaceutical drugs than any other developed country. Insulin that costs $30 in Canada costs $300 in the US. This is not because US consumers get better versions of the drugs — they're frequently identical. It's because the US healthcare system lacks the price negotiation mechanisms that every other developed country uses.

ZDoggMD has been direct: drug pricing in the US is set by a combination of patent protection, regulatory barriers to generic competition, pharmacy benefit manager opacity, and the political influence that pharmaceutical companies exercise to prevent meaningful price regulation. The physician in the exam room prescribing a medication has no reliable information about what that medication will cost the patient. This is a system design failure with real patient consequences — patients who can't afford prescriptions don't take them.

Direct-to-Consumer Advertising

The US and New Zealand are the only developed countries that permit direct-to-consumer pharmaceutical advertising. ZDoggMD has examined the consequences: patients coming into appointments asking for specific medications by brand name, creating pressure on physicians who may have no clinical reason to prescribe the advertised drug.

This adds to the documentation burden: conversations about why the advertised medication isn't appropriate — or why the generic is equivalent — need to be captured in the note. The DTC advertising model turns patients into marketing channels and creates clinical work that serves the pharmaceutical company's revenue rather than the patient's health.

Physician Influence: The Sunshine Act and What Comes After

The Physician Payments Sunshine Act made pharmaceutical payments to physicians publicly searchable. ZDoggMD has been transparent about his own relationships with industry and is critical of the conflicts of interest that industry payments create. His position: physicians who receive industry money should disclose it clearly and comprehensively. Patients have a right to know when the physician recommending a medication has a financial relationship with its manufacturer.

ZDoggMD on pharmaceutical industry and drug pricing:

No Industry Conflicts Here

NoPajamaTime is physician-founded, physician-focused, and has no pharmaceutical industry relationships. We eliminate midnight charting. That's the whole product.